Just micro-dosed a few minutes ago to stay on theme for this 2022 technical outlook. Psychedelics. 2021 was the year I was introduced to the benefits of psychedelics. Mind…
Psychedelics
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…
Quite the price action on Filament Health yesterday. The company is all about paving the way for the first ever natural psychedelic drug. Filament Health Corp. operates as a…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January. The fund closed…
Filament Health Corp. (FH.NE) (“Filament”) announced today that it will be participating in three conferences throughout December 2021. These conferences include the Horizons: Perspectives on Psychedelics Conference, H.C. Wainwright 2nd…
The psychedelics space is loaded with over-valued unicorns and also-rans, making it difficult for investors to find real growth opportunities. Here are some companies in the sector that have…
Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a hit. This could just…
In this episode, we take a look at 3 Canadian psychedelic stocks with potential: MYND Life Science (MYND.C), Mind Cure Health Inc. (MCUR.C), NeonMind Biosciences (NEON.C). We briefly go…
Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top of industry advances and…